mTOR inhibition reverses feline cardiac hypertrophy
PrimaryTriviumVet's sirolimus/rapamycin program is based on the causal theory that intermittent low-dose delayed-release rapamycin inhibits mTOR signaling in hypertrophied feline myocardium, producing disease-modifying effects in hypertrophic cardiomyopathy rather than only symptomatic control. The expected mechanism is suppression of myocardial hypertrophy programs, stimulation of autophagy, and broader cellular remodeling/metabolic effects in cardiac tissue. Testable predictions are that treated cats with subclinical hypertrophic cardiomyopathy should show reduced or slowed ventricular hypertrophy, beneficial left-ventricular remodeling, dose-responsive transcriptomic signals of reduced hypertrophy, increased autophagy-related signatures, and myocardial proteomic changes consistent with remodeling and improved disease biology.
Popperian evaluation
The premise is biologically credible: rapamycin inhibits mTOR, and the proposed downstream effects, reduced hypertrophy programs, more autophagy signaling, and cardiac remodeling, fit known mTOR biology. The feline-specific claim is less settled. The evidence includes short-term molecular and safety signals in cats, but the central premise still depends on whether once-weekly delayed-release dosing produces enough myocardial exposure over time to change disease course.
Supporting evidence: The theory directly links intermittent delayed-release rapamycin to mTOR signaling in hypertrophied feline myocardium.; The evidence context reports dose-responsive transcriptomic signals consistent with reduced myocardial hypertrophy.; The evidence context reports autophagy-related transcriptomic changes and myocardial proteomic changes consistent with remodeling.
Counter evidence: The myocardial exposure assumption is still listed as an assumption, not a settled fact.; Short-term transcriptomic and proteomic shifts may not equal durable disease modification in feline hypertrophic cardiomyopathy.; Generalization from a small hereditary feline HCM colony to client-owned cats remains uncertain.
The theory explains several observed signals with one coherent mechanism: mTOR inhibition could reduce hypertrophy signaling, increase autophagy signatures, and alter cardiac proteomics. That is a good fit. The weak point is clinical causality. Safety, platelet effects, and short-term molecular changes can coexist with the theory without proving that rapamycin reverses feline cardiac hypertrophy. We have a plausible mechanistic explanation, but the disease-modifying claim still outruns the evidence.
Supporting evidence: A prior client-owned feline subclinical non-obstructive HCM study reported beneficial left-ventricular remodeling.; Transcriptomic differences between low- and high-dose groups supported suppression of myocardial hypertrophy.; Myocardial proteomic differences between treated and control cats suggested cellular remodeling and metabolic effects.
Counter evidence: The strongest reported signals are biomarkers and remodeling measures, not hard clinical endpoints.; Platelet activation changes show broader cardiovascular biology, but they do not directly prove myocardial hypertrophy reversal.; Alternative explanations, including short-term adaptive molecular responses or colony-specific biology, remain open.
This theory is highly testable. It predicts measurable changes in ventricular hypertrophy, left-ventricular remodeling, transcriptomic hypertrophy signals, autophagy signatures, and myocardial proteomics. A controlled study could falsify it cleanly if treated cats fail to show slowed wall thickening, dose-linked molecular effects, or remodeling beyond control animals. The cat either remodels in the predicted direction or it does not.
Supporting evidence: The theory predicts reduced or slowed ventricular hypertrophy in treated cats with subclinical HCM.; It predicts beneficial left-ventricular remodeling.; It predicts dose-responsive transcriptomic signals and proteomic changes tied to cardiac remodeling.
Counter evidence: Some endpoints, especially proteomic changes described as consistent with improved biology, need prespecified thresholds to avoid loose interpretation.; Biomarker predictions are easier to satisfy than clinical disease-modification predictions.
Reasoning tree
Public endorsements
No public statement, quote, authored publication, or attributed remark from Aisling Farrell appears in the provided evidence. The rapamycin pilot paper supports the company theory, and a LinkedIn post praises the RapaCat results, but neither is tied to Farrell. On this record, she stays silent.
The provided evidence does not show any public statement by Gemma Kennedy about TriviumVet's rapamycin theory in feline HCM. The Wayback snapshot mentions Susan Kennedy representing TriviumVet at an EMA SME event, but it does not attribute any view on the mechanism or program theory to Gemma Kennedy. The LinkedIn post is by Sarah O'Connor, not Gemma Kennedy.
Louise Grubb is publicly identified as TriviumVet's managing director/CEO, but the provided record only establishes her role. It does not contain any public statement from her about the rapamycin program's theory that mTOR inhibition reverses feline cardiac hypertrophy, and no quotes are provided. On this evidence, she stays silent on the theory.
Evidence publication IDs: af496e33-108f-49d3-8ab4-2f4943c0fce0
The dossier provides no public quote or publication from Mena Fitzgerald on this theory. The only relevant public records here are company materials and patent records tied to Stuart Fitzgerald and TriviumVet's rapamycin program, which do not show Mena Fitzgerald personally endorsing, mentioning, or contradicting the claim that mTOR inhibition reverses feline cardiac hypertrophy.
There is no public evidence here that Michael Costello has endorsed, mentioned, or challenged TriviumVet's theory that intermittent delayed-release rapamycin can modify feline hypertrophic cardiomyopathy through mTOR inhibition. The only listed publication is a 2026 dog neurology questionnaire study on Chiari-like malformation and syringomyelia, which does not address feline cardiac hypertrophy, rapamycin, mTOR, or TriviumVet.